Astellas: C3 Prize for cancer care innovation
Astellas Pharma US has awarded its sixth annual Changing Cancer Care (C3) Prize to Aimee DeGolyer, founder and CEO of REPROSENT. The $100,000 award is given to innovative, non-treatment solutions intended to improve cancer care for patients, caregivers, and the oncology community.
"In alignment with Astellas' patient-centric approach focused on supporting innovative health solutions beyond medicine through a deep understanding of the patient experience, REPROSENT honors the perspective and needs of patients with an outcomes-based digital app that complements in-person touchpoints," said Anthony Yanni, senior vice president and global head of patient centricity with Astellas. "We are honored to fuel this year's winning idea, which is based on real-world experience and has the potential to meaningfully help people living with cancer."
After losing her father in 2020 to a cancer immunotherapy adverse reaction, DeGolyer founded REPROSENT and developed a mobile app to help cancer patients track their own symptom data, enabling them to have greater control in their treatment. The app aims to reduce clinical team burden, drive deeper understanding of the patient's daily data and improve outcomes.
